Waldencast 2Q22 Investor Results

OBAGIⓇ $99.7M 1H 2022 Net revenue¹ 77.1% 1H 2022 Gross Profit +201 BPS vs. YA +18.1% 1H 2022 Net revenue growth 24.4% 1H 2022 Pro Forma Adj. EBITDA4 -374 BPS vs. YA $56.6M Q2 2022 Net revenue¹ 80+ Patents worldwide² +10.9% Q2 2022 Net revenue growth #1 perceived best performing brand among US providers ³ 12022 OBAGI financials exclusive of China business 2 OBAGI management information 3 "2020 Kline Physician-Dispensed Skincare: U.S. Perception & Satisfaction Survey," Kline & Company 4 Reconciliations of Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA Margin to net income, the most directly comparable GAAP financial measure, are included in the appendix of this presentation.

View entire presentation